Potential future targets for treating ocular neovascularization

Fina C Barouch; Joan W Miller

doi:10.1016/j.ohc.2006.05.004

Potential future targets for treating ocular neovascularization

Ophthalmol Clin North Am. 2006 Sep;19(3):401-9. doi: 10.1016/j.ohc.2006.05.004.

Authors

Fina C Barouch¹, Joan W Miller

Affiliation

¹ Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, USA.

PMID: 16935215
DOI: 10.1016/j.ohc.2006.05.004

Abstract

A wide variety of mediators likely contribute to ocular NV and these can serve as potential targets for the treatment of ocular NV. Several targets have already been validated in preclinical models and are being explored in clinical studies. In addition, targeting other processes besides angiogenesis, such as inflammation and apoptosis, may be beneficial in the treatment of ocular NV. Combined approaches with the use of several angiogenesis inhibitors or anti-inflammatory agents may show synergistic effects in treating ocular NV.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Angiogenesis Inhibitors / therapeutic use*
Animals
Cell Survival / drug effects
Disease Progression
Endothelium, Vascular / drug effects
Endothelium, Vascular / pathology
Eye Diseases / drug therapy
Eye Diseases / pathology*
Humans
Neovascularization, Pathologic / drug therapy*
Neovascularization, Pathologic / metabolism
Neovascularization, Pathologic / pathology
Treatment Outcome

Substances

Angiogenesis Inhibitors